HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on KalVista Pharma (NASDAQ:KALV) and maintained a $20 price target.
July 15, 2024 | 10:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on KalVista Pharma and maintained a $20 price target.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100